Patients' Characteristics and Determination of FasL Expression in Native Malignant Plasma Cells
| Patient No. . | Age (yr) . | Treatment . | Paraprotein . | BM Plasma Cells (%) . | FasL Expression (MSFI)* . |
|---|---|---|---|---|---|
| 1 | 55 | No | IgGλ | 19 | 1.06 |
| 2 | 52 | Yes | IgGλ | 2 | 1.25 |
| 3 | 76 | No | Nonsecretory | 50 | 1.46 |
| 4 | 70 | No | IgG-κ | 40 | 1.30 |
| 5 | 69 | Yes | IgG-λ | 5 | 1.13 |
| 6 | 65 | No | κ-Light chain | 35 | 1.26 |
| Patient No. . | Age (yr) . | Treatment . | Paraprotein . | BM Plasma Cells (%) . | FasL Expression (MSFI)* . |
|---|---|---|---|---|---|
| 1 | 55 | No | IgGλ | 19 | 1.06 |
| 2 | 52 | Yes | IgGλ | 2 | 1.25 |
| 3 | 76 | No | Nonsecretory | 50 | 1.46 |
| 4 | 70 | No | IgG-κ | 40 | 1.30 |
| 5 | 69 | Yes | IgG-λ | 5 | 1.13 |
| 6 | 65 | No | κ-Light chain | 35 | 1.26 |
MSFI was determined by immunofluorescence staining and FACS analysis and calculated as the ratio of the MSFI achieved with anti-FasL MoAb/isotype-matched control MoAb. Mean of two experiments is given. A ratio >1.2 was considered as positive.